View live charts, options flow & technicals for Bio-Techne Corporation →
Open Dashboard
Bio-Techne Corporation (TECH) is a healthcare company in the biotechnology industry with $1.22B in trailing revenue trading at a 62.6× trailing P/E — analyst consensus: none.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Key Statistics
Market Cap
$11.39B
Revenue (TTM)
$1.22B
EPS (TTM)
$1.16
EPS (Fwd est.)
$2.31
Employees
3,000
Trailing P/E
62.59
Forward P/E
31.48
PEG Ratio
2.11
Price / Sales
9.37
Price / Book
5.38
EV / EBITDA
34.15
Beta (5Y)
1.27
Analyst Consensus
Consensus
None
Analyst Price Target
-2.6% downside
Target: $70.73
Annual Revenue & Net Income
RevenueNet Income
'23
$1.14B
$290.00M
'24
$1.16B
$170.00M
'25
$1.22B
$70.00M
'26
$1.22B
$180.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$0.52
$0.52
Miss (+0.1%)
May 2026
$0.53
$0.53
Miss (-0.8%)
Feb 2026
$0.46
$0.43
Beat (+5.8%)
Nov 2025
$0.42
$0.42
Miss (-0.4%)
Next Earnings Report
Bio-Techne Corporation is next expected to report earnings on 09 Nov 2026.
Profitability
66.2%
27.9%
15.0%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
1.3%
Return on Equity
9.0%
Return on Assets
6.7%
Balance Sheet
Cash & Equivalents
$270.00M
Total Debt
$290.00M
Net Position
$20.00M (net debt)
Free Cash Flow (TTM)
$230.00M
Debt / Equity
13.71
Share Ownership
Institutions 115.1%
Insiders 0.3%
Institutional figure exceeds 100% due to short selling
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of li…
What is TECH's market cap?
Bio-Techne Corporation has a market capitalization of approximately $11.39B.
What is TECH's P/E ratio?
Bio-Techne Corporation trades at a trailing P/E ratio of 62.6x and a forward P/E of 31.5x, which is above the broad market average of ~25x.
How much revenue does TECH generate?
Bio-Techne Corporation generated $1.22B in trailing 12-month revenue.
What do analysts say about TECH?
The analyst consensus rating for Bio-Techne Corporation is none, with a mean price target of $70.73. That implies -2.6% upside from the current price.
When does TECH report earnings?
Bio-Techne Corporation is next scheduled to report earnings on 09 Nov 2026.
Does TECH pay a dividend?
Yes. Bio-Techne Corporation pays a dividend with a current yield of 0.44%, at an annual rate of $0.32 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Bio-Techne Corporation on Apsis Markets.